4.5 Interaction  with  other  medicinal products  and other  forms  of interaction  
 Currently,  there  are limited  data on possible  drug interactions  with Mab 
 Thera.  
 In CLL patients, co -administration with Mab 
 Thera did not appear to have an effect on the pharmacokinetics of fludarabine or cyclophosphamide. In addition, there was no apparent effect of  fludarabine  and cyclophosphamide  on the pharmacokinetics  of Mab 
 Thera.  
 Co-administration with methotrexate had no effect on the pharmacokinetics of Mab 
 Thera in  rheumatoid  arthritis  patients.  
 Patients with human anti -mouse antibody (HAMA) or anti -drug antibody (ADA) titres may have  allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal  antibodies.  
 In patients with rheumatoid arthritis, 283 patients received subsequent therapy with a biologic  DMARD following Mab 
 Thera. In these patients the rate of clinically relevant infection while  on Mab 
 Thera was 6.01 per 100 patient years compared to 4.97 per 100 patient years following treatment  with the biologic  DMARD.  
 
